ArticleThe International journal of eating disorders2026
Dietetic-Led Cognitive-Behavioral Therapy for Avoidant/Restrictive Food Intake Disorder: Feasibility, Acceptability, and Proof-of-Concept.
Article in The International journal of eating disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dietetic-Led Cognitive-Behavioral Therapy for Avoidant/Restrictive Food Intake Disorder: Feasibility, Acceptability, and Proof-of-Concept.The International journal of eating disorders · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveCognitive-Behavioral Therapy for Avoidant/Restrictive Food Intake Disorder (CBT-AR) is an emerging treatment for ARFID, but to date, it has only been delivered by mental health clinicians. Given the relevance of nutrition to treatment goals, we adapted the treatment to be dietetic-led (D-CBT-AR).
methodWe conducted a pilot trial of D-CBT-AR. Participants self-referred to a multidisciplinary eating-disorder clinic in Brisbane, Australia, and attended in person or virtually. Participants rated D-CBT-AR on acceptability and feasibility. We also measured changes in ARFID psychopathology, Body Mass Index, and co-morbid psychopathology.
resultsOf the 12 participants offered D-CBT-AR, 92% (n = 11) took up the treatment, and 72% (n = 8) completed, with a median treatment length of 33 weeks. The majority of completers rated D-CBT-AR above benchmarks on feasibility (89%) and acceptability (78%). Using intent-to-treat analyses, participants reported large and significant improvements in ARFID psychopathology on all subscales of the Pica, ARFID and Rumination Disorder Interview. They incorporated a median of 26 new foods. For those who were weight-suppressed, Body Mass Index increased by 1.5 bands from pre- to post-treatment, though effects were non-significant. Participants also reported large and significant reductions in clinical impairment, depression, and stress. Additionally, at 6-months post-treatment, five participants met remission criteria. DISCUSSION: The trial shows proof-of-concept for the feasibility and acceptability of D-CBT-AR. Although requiring replication in larger and randomized controlled trials, our findings highlight the potential of D-CBT-AR to expand the types of professionals who could effectively deliver CBT-AR, thereby increasing access to care for individuals living with ARFID.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.